JOSEPH RICHARD CREEKMORE
Pharmacy in Wilmington, DE
License number
Pennsylvania RP444511
Category
Pharmacy
Type
Pharmacist
Address
Address
2
Wilmington, DE 19808
Pennsylvania
Pennsylvania
Personal information
See more information about JOSEPH RICHARD CREEKMORE at radaris.comName
Address
Phone
101 Winterbury Ln, Wilmington, DE 19808
938 S Franklin St, Wilkes Barre, PA 18702
Wilkes Barre, PA
101 Winterbury Ln, Wilmington, DE 19808
79 Hill St, Wilkes Barre, PA 18702
Professional information
Pharmaceutical Compositions
US Patent:
6399104, Jun 4, 2002
Filed:
Jun 15, 2000
Appl. No.:
09/581612
Inventors:
Joseph R Creekmore - Wilmington DE
Susan J Corvari - Nashua NH
Susan J Corvari - Nashua NH
Assignee:
AstraZeneca UK Limited - London
International Classification:
A61K 916
US Classification:
424490, 424489, 424464, 424465, 424468, 424472, 424451, 424456, 424452, 424457, 424497
Abstract:
A dry powder layering process for preparing pharmaceutical compositions of the leukotriene antagonist zafirlukast. The process forms coated beads suitable for sprinkling on to food and drink.
Pharmaceutical Compositions
US Patent:
6548513, Apr 15, 2003
Filed:
Aug 4, 2000
Appl. No.:
09/633114
Inventors:
Joseph R Creekmore - Wilmington DE
Norman A. Wiggins - Wilmington DE
Norman A. Wiggins - Wilmington DE
Assignee:
AstraZeneca AB - Sodertalje
International Classification:
A61K 31505
US Classification:
514275, 514256, 514557, 544322
Abstract:
The present invention relates to pharmaceutical compositions and more particularly to a pharmaceutical composition containing (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically-acceptable salt thereof as the active ingredient and an inorganic salt in which the cation is multivalent.
Pharmaceutical Compositions
US Patent:
6316460, Nov 13, 2001
Filed:
Aug 4, 2000
Appl. No.:
9/633064
Inventors:
Joseph R Creekmore - Wilmington DE
Norman A. Wiggins - Wilmington DE
Norman A. Wiggins - Wilmington DE
Assignee:
Astrazeneca AB - Sodertalje
International Classification:
A61K 31505, A61K 3119
US Classification:
514275
Abstract:
The invention concerns a pharmaceutical composition comprising the HMG CoA reductase inhibitor (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrim idin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof as the active ingredient, which remains stable over a prolonged period.
Pharmaceutical Composition
US Patent:
8632807, Jan 21, 2014
Filed:
May 18, 2012
Appl. No.:
13/475525
Inventors:
Joseph Richard Creekmore - Wilmington DE, US
Sanjeev Hukmichand Kothari - Wilmington DE, US
Bradford J. Mueller - Wilmington DE, US
Yingxu Peng - Wilmington DE, US
Sanjeev Hukmichand Kothari - Wilmington DE, US
Bradford J. Mueller - Wilmington DE, US
Yingxu Peng - Wilmington DE, US
Assignee:
AstraZeneca UK Limited - London
International Classification:
A61K 9/32, A61K 31/505, A61K 9/36
US Classification:
424480, 424494, 424497, 514275
Abstract:
The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture.